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Introduction
The 1950s heralded a golden age for psychiatric drug discovery; 
for the first time, compounds capable of treating serious mental 
disturbances were found that, despite their shortcomings, proved 
the pharmacotherapy of mental disorders was both possible 
and effective. Not only did these early treatments unlock the 
Victorian asylums and allow a more humane attitude to mental 
illness, they also led to the founding of modern neuroscience 
approaches to understanding the function and dysfunction 
of the most complex object in the universe- the human brain. 
This first wave of drug discovery and development took place 
in the absence of any meaningful knowledge of the underlying 
biological mechanisms, but rather occurred via serendipity 
coupled with careful observation. First generation compounds 
were consumed in vast amounts and the nascent pharmaceutical 
industry became immensely wealthy as the need for major and 
minor tranquillisers prevailed. Yet people were not ‘cured’ 
and the drugs themselves had sometimes life threatening side 
effects as well as the risk of addiction and dependence. It took 
many years to understand mechanisms of action to the point 
where drugs could be designed to target specific pathways and 
targets. Eventually, mechanisms of action were unveiled and 
there followed a period when effort was concentrated on the 
removal of undesirable side effects. As the key molecular targets 
became better understood, rivalry between companies to obtain 
a competitive advantage intensified and the focus switched to 
improving efficacy. As the low hanging fruit were rapidly picked, 
financial competition lead not to better drugs, but to mergers and 
acquisitions until it was realised that such approaches were more 
destructive than creative; and important skill sets were being 
discarded in the name of management efficiency. 
As the scarcity of new compounds was realised, the genomic 
revolution swept in and promised a plethora of new molecular 
drug targets, with the hope that statistical association with a 
disease would provide sufficient justification for the allocation 
of the resources needed to bring compounds to market. It was 
hoped that psychiatric diseases would be monogenic; a single 
gene mutation which, once identified, would refocus the 
objective to finding a means of overcoming the deficiency or 
calming the over-activity. However, intense complexity has 
prevented unambiguous identification of genes and/or molecular 
targets for mental health disorders, as has happened to some 
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extent in other fields, such as oncology or cystic fibrosis. 
Psychiatric disorders have been shown to be highly polygenetic 
with significant biological impact coming from genes, the 
environment and the unique life histories of the individuals. 
Furthermore, there is increasing evidence that many psychiatric 
disorders, for example depression and schizophrenia, are not 
single disorders but rather encompass a range of phenotypes 
that differ in causation and therefore will most likely require a 
different treatment approach.
The best example of this drug discovery model is the loss of 
function mutation of the SCN9A gene, which encodes the 
voltage gated sodium channel Nav1.7 and causes congenital 
insensitivity to pain in both humans and mice in which the 
gene has been experimentally deleted [1,2]. Accordingly, small 
molecule inhibitors of Nav1.7 were sought, especially since 
the null mutant mice otherwise appear healthy, suggesting 
such compounds, if selective, would be free of the cardiac side 
effects associated with broad spectrum sodium channel blockers 
[3]. Intense effort has indeed identified potent and selective 
compounds, but in animals, they provide only relatively weak 
analgesic activity e.g. ProTx-ll [4], and even neutralising 
monoclonal antibodies provides only partial and transient 
pain relief [5]. The reason for this discrepancy between theory 
and practice is a timely lesson to remember that life did not 
evolve to serve the interests of pharmaceutical companies- 
biological mechanisms are always more complex than we like 
to think. Despite the inconvenience, our capacity to understand 
that complexity is impressively demonstrated by the work of 
scientists at University College London, who demonstrated the 
reason behind this weak analgesic effect, despite potent Nav1.7 
inhibition, is due to profound alterations in gene expression as a 
result of the mutation, leading to an upregulation of endogenous 
opioids [6]. For that reason, Minett et al. used the opioid receptor 
antagonist naloxone in Nav1.7 mutant mice and substantially 
reversed the behavioural analgesia. Remarkably, Minett et al. 
had access to a human subject with SCN9A deletion in which 
there was a dramatic reversal of analgesia on infusion of 
naloxone. This work is a prime example of how we have moved 
a long way from the serendipitous discoveries of the past; the 
complex reasons behind the failures of today now provide a 
breeding ground for ideas and new knowledge to pave the way 
for future discoveries.
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An analysis of successes and failures within the global 
pharmaceutical industry by Morgan et al. highlighted the 
pitfalls we often fall into. On analysis of 44 programs from 
Pfizer, the majority failed to demonstrate efficacy; and a large 
number of cases (43%) actually failed to adequately test their 
hypothesis. From these investigations, three key factors were 
found to clearly contribute to failure; i) lack of exposure at the 
site of action, ii) lack of target binding, and iii) lack of functional 
pharmacological activity [7]. 
Recent advances may enable us to tackle these problems, 
however highly specialised expertise and of course, adequate 
funding is required. Nevertheless, new preclinical technologies 
allow for valid, translational and relatively cheap ways to face 
the problem:
In the first instance, a key hurdle is that studies are not 
always backed up by pharmacokinetic evidence that the dose 
administered will provide appropriate tissue concentrations 
at the molecular target. Proton Emission Technology (PET) 
studies using selective radioligands may go some way to tackle 
this problem, by clearly showing that the compound enters the 
brain and occupies its receptor or target. 
Next, it needs to be demonstrated that occupation of the target 
by the drug results in a pharmacodynamic effect. To show 
functional activity after target engagement requires a biomarker 
that indicates the system of interest has been pharmacologically 
activated. From a human neuropsychiatric perspective, 
functional neuroimaging such as fMRI BOLD would be the 
technology of choice, as it is able to demonstrate the brain 
structures associated with activation of the molecular target. 
Furthermore, fMRI also allows the subject to be monitored 
whist simultaneously performing a task relevant to the disease 
of interest, and thus potentially providing the beginnings of 
target validation. 
Accomplishing this in small laboratory animals, however, 
is complicated by the necessity to minimise movement by 
using anaesthetic, which may subsequently confound results. 
Nonetheless, since the BOLD measure is dependent on changes in 
tissue oxygen concentration, this can be determined in small brain 
regions in freely moving behaving rodents using the technique 
of oxygen amperometry [8]. Here, a small carbon electrode is 
implanted into a region of interest and when a potential of -0.75 
millivolts is applied, tissue oxygen is oxidised and the resultant 
electron flow is proportional to the concentration of oxygen. Using 
an appropriately designed tether, the animal can be placed in a 
suitable environment where stimuli can be applied and responses 
can be monitored and quantified. If the animal is in an operant box 
it can be trained to press a lever and obtain a food reward. This 
can be equated to a monetary incentive task which in the human 
BOLD paradigm leads to activation of the nucleus accumbens, a 
signal that is magnified when the value of the reward is increased 
[9]. Similarly in rodents, oxygen concentration is increased when 
the reward is increased from one food pellet to two [10]. Even 
more interesting, the slow 90.1-100 Hz inter regional oscillations 
that characterise the default mode resting state are also seen 
with oxygen amperometry, with nodes and edges very similar to 
the connectivity patterns seen in anaesthetised rats undergoing 
BOLD measurements. Even more striking from a translational 
perspective are the similarities in drug induced changes to the 
strength of interregional coherence seen in the rat, compared to 
those seen in man. For example, it has been shown that ketamine 
enhances the connectivity between the anterior cingulate cortex 
and the hippocampus of man and rodents and the strengths wax 
and wane as the animal is signalled to pay attention to changes 
in reinforcement schedule [11]. Indeed, the unique effects of 
ketamine (via stimulation of AMPA receptors) are well worth 
investigating for its antidepressant activity, as predicted some 
time ago by its efficacy in the reviled mouse forced swim test 
[12,13].
The more it becomes possible to make detailed investigations of 
brain circuitry involved in drug and behavioural responses, the 
greater the translational validity of clinical and preclinical proof 
of concept investigations will be.
Once it has been determined that a compound is present at 
the receptor, binds with sufficient affinity and has a biological 
effect, even then there are hurdles to face in the interpretation of 
the results. The quantification of rodent behaviour has long been 
thought a weak point of psychiatric drug discovery. However, 
despite the ongoing queries over the translational relevance 
of some behavioural tasks [14], recent evidence shows the 
results themselves do have excellent reproducibility, when 
experiments are carefully managed and replicated in different 
laboratories [15]. A simple administrative approach to ensure 
good reproducibility going forwards might be to ask authors of 
all journal submissions to present a signed statement that the 
key findings of the paper have been replicated independently by 
other investigators in the lab.
There are clearly some great obstacles in the way of developing 
new psychiatric medications, however new innovative ways of 
approaching the puzzle could (and currently are) pave the way 
to a brighter future of drug discovery.
One concept which has invigorated the field, and is providing 
an exciting new spin, is the finding that many diseases have 
an inflammatory component and could be tackled by anti-
inflammatory compounds. For example, a schizophrenia-
like state can be induced in subjects who have generated 
autoimmune antibodies to the NMDA receptor and NMDA 
receptor antagonists have been used for many years as acute 
pharmacological rodent models of schizophrenia [16,17]. 
NMDA receptor immunity, at the very least, lends a strong 
degree of validity to this animal model, even more so if the 
antibody could be prepared in sufficient amounts to be used in 
the animal model for a potentially more accurate recapitulation 
of the disease. 
Another huge new technology is the conditioning of patient 
cells into neurons, and the subsequent creation of personalised 
cellular disease models [18]. This approach enables comparison 
of metabolic and functional differences between those affected 
with a psychiatric disorder and models of unaffected individuals. 
Differences could be determined and investigated for metabolic 
and functional errors, which could lead to novel and validated 
drug targets. Scientists at the University of Luxembourg have 
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now successfully created three-dimensional brain-like cultures 
from skin samples. These cultures display different cell types 
which develop, connect, signal and exchange metabolic 
products, just like an active brain [19].
Finally, the potential for High Throughput Screening (HTS) as 
a drug discovery tool is becoming more apparent as a powerful 
route towards greater functional selectivity and clinical efficacy. 
The sorry tale of cortico-releasing factor (CRF) receptor 
antagonists is a prime example of how HTS may be necessary 
to make any headway in some cases. Multiple attempts with 
high quality CRF receptor antagonists have failed to show 
antidepressant efficacy [20-22], despite considerable evidence 
supporting the importance of the pituitary-adrenal axis in the 
pathophysiology of the disease [23]. Although there is much 
to support the potential of these compounds to be efficacious 
in the treatment of anxiety and depression, clinical trials of 
compounds having good drug-like characteristics have all failed 
without a hint of efficacy. A study by Zhang et al, reasoned that 
it is the CRF receptors in a specific area of the hypothalamus 
(Para ventricular nucleus) which are markedly involved in 
controlling CRF secretion [24]. Zhang et al. reasoned that global 
blockade of CRF receptors throughout the brain might obscure 
effects and they set about to genetically engineer the deletion 
of the CRF receptor specifically in the para ventricular neurons 
of the hypothalamus. The CRF receptor was depleted only 
from a group of cells expressing the transcription factor NIN-
1, which is necessary for hypothalamic development [25,26]. 
This selective deletion gave a very robust anxiolytic phenotype, 
which may explain the lack of clinical efficacy after global CRF 
blockade. The question now is to identify a way of screening for 
antagonists possessing affinity only for the NIN-1 containing 
cells. It is possible that large volume screening of a mega sized 
sample collection could reveal such a compound.
Another great example of the promise of HTS is PZM21, an 
opioid agonist with major differences from all that has gone 
before- all the analgesic power of the opioids without respiratory 
depression. PZM21 was found by screening for novel opioid 
receptor agonists whilst looking for a compound devoid of action 
on respiratory pathways from a set of 3 million commercially 
available compounds [27]. Addiction potential has yet to be 
defined, but it shows the HTS approach can yield success. 
Likewise, the same logic could be applied to the metabotropic 
glutamate allosteric modulators which have very exciting in 
vivo behavioural profiles as potential anti-schizophrenic and 
wake promoting pro-cognitive molecules, but that cause cortical 
necrosis [28].
By screening out unwanted properties through concentrating 
on a very large sample of different molecules, we mimic the 
serendipitous approach of earlier times. However, this time, we 
base the screening on much stronger target validation by knowing 
beforehand what it is we do and do not want. If target validation 
has been done diligently, the chances of achieving positive 
effects in a human Proof of Concept experimental medicine study 
will be much higher and faster than ever before. Especially if all 
the lessons about optimising dose, providing evidence of target 
engagement, and of target activation/inhibition are heeded. With 
the availability of techniques like oxygen amperometry, a fully 
translational animal neuroimaging Proof of Concept study can 
be performed. Even analysis of local field potential recording, 
or unit activity, has now progressed to the point that drug 
induced engagement of circuitry can be confirmed in preclinical 
experimentation, saving both time and cost.
There is a general sense of gloom surrounding psychiatric drug 
discovery at present. Since those golden days of the 1950s, 
pharmaceutical companies and universities alike have strived 
to develop new drugs with improved therapeutic profiles 
and reduced side effects. Unfortunately, this process has not 
advanced as fast as it should, partly reflecting the complexity 
of brain disorders, the lack of meaningful ‘biomarkers’, an 
emphasis on developing drugs that predominantly duplicate the 
action of existing drugs and a reliance on dated and simplistic 
animal models. The scope and investment in psychiatric 
drug discovery research is highly sensitive to success, and of 
late there has been very little. Today, there is a deep rooted 
pessimism that without new focus and drive, the next generation 
of pharmaceuticals cannot be found; the trees have been 
stripped of their low hanging fruit. As a result, many companies 
have withdrawn or reduced the size of their psychiatric drug 
discovery teams. Despite this, we would argue that now is the 
wrong time to withdraw- the cost of brain disorders in terms of 
human suffering and economic burden to society is too high, 
and is rising.
The pharmaceutical industry will not inspire the next generation 
of investigators by walking away from difficult scientific 
problems. It is hoped that this short review will lessen the 
pessimism surrounding psychiatric drug discovery and 
contribute to attracting the pharmaceutical industry back into 
the field. Though still risky and expensive, the CEOs would do 
well to remember the huge financial and societal gain from those 
initial compounds, which were vastly inferior to what could 
become available in the future if the best new technologies are 
correctly exploited, and we have faith in those scientists who 
have dedicated their lives to this field.
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